Can psoriasis patients safely cut their biologic doses in half?

NCT ID NCT04340076

Completed Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

Summary

This study investigated whether patients with stable, mild psoriasis could safely reduce the dose of their advanced biologic medications (IL-17 or IL-23 inhibitors) without their symptoms getting worse. 244 patients who had been doing well on standard doses were randomly assigned to either try a gradual dose reduction or continue their usual care. The main goal was to see if the lower dose worked just as well at keeping the skin condition under control over 18 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AZ Maria Middelares

Ghent, Belgium
AZ St Lucas

Ghent, Belgium
Amphia Hospital

Breda, Netherlands
Bravis hospital

Bergen op Zoom, Netherlands
CHU Liege

Liège, Belgium
Catharina hospital

Eindhoven, Netherlands
Dermatologie Maldegem

Maldegem, Belgium
Erasmus MC

Rotterdam, Netherlands
Ghent University Hospital

Ghent, 9000, Belgium
Maastricht UMC

Maastricht, Netherlands
Máxima Medisch Centrum

Veldhoven, Netherlands
Radboudumc

Nijmegen, 6500HB, Netherlands
Slingeland hospital

Doetinchem, Netherlands
UCL Saint Luc

Leuven, Belgium
ULB Erasme

Brussels, Belgium
UMC Groningen

Groningen, Netherlands
UMC Utrecht

Utrecht, Netherlands
UZ Leuven

Leuven, Belgium
Ziekenhuisgroep Twente

Almelo, Netherlands

Conditions

Explore the condition pages connected to this study.

PSORIASIS PSORIASIS VULGARIS